Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2.
Tamura R, Fujioka M, Morimoto Y, Ohara K, Kosugi K, Oishi Y, Sato M, Ueda R, Fujiwara H, Hikichi T, Noji S, Oishi N, Ogawa K, Kawakami Y, Ohira T, Yoshida K, Toda M.
Tamura R, et al. Among authors: kosugi k.
Nat Commun. 2020 Apr 21;11(1):2028. doi: 10.1038/s41467-020-16007-z.
Nat Commun. 2020.
PMID: 32317644
Free PMC article.